Online citations, reference lists, and bibliographies.
← Back to Search

Are Women With Urogenital Atrophy Symptomatic?

G. Davila, A. Singh, I. Karapanagiotou, S. Woodhouse, K. Huber, S. Zimberg, J. Seiler, S. Kopka
Published 2003 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
OBJECTIVE The purpose of this study was to determine the degree of correlation between physical signs of genital atrophy and symptoms that are suggestive of atrophic vaginitis. STUDY DESIGN Female volunteers (n = 135; mean age, 69 years) rated the presence and severity (rating, 0-3) of vaginal atrophy symptoms. The presence and severity of vaginal mucosal changes, which included vaginal pH (0-3), were recorded during a pelvic examination. A vaginal cytologic maturation value was performed. Symptoms, signs, pH, and maturation value were correlated by the Spearman rank test. RESULTS Symptom scores were low (mean, 0.41; range, 0-2.6). Symptoms were only weakly correlated with physical findings (r = 0.14) and not with maturation value (r = 0.06) or age (r = -0.004). There was a moderate correlation between physical examination score and maturation value (r = -0.48). In women > or =65 years old, symptom score and physical examination score were correlated weakly (r = 0.25). Low pH correlated well with high maturation value (r = -0.52). Women who were undergoing estrogen therapy had higher symptoms scores (P =.0007) and maturation values (P =.0002) than women who were not undergoing therapy. CONCLUSION Although urogenital atrophy occurs universally after menopause, most elderly women are minimally symptomatic. Those women on estrogen replacement therapy may be more symptomatic. Symptoms alone should not be used as a guide for the initiation of estrogen therapy.
This paper references
Sex and menopause: defining the issues.
P. Sarrel (1985)
Effect of vulvovaginal estrogen on sensorimotor response of the lower genital tract: a randomized controlled trial.
D. Foster (1999)
Estrogen therapy in the management of problems associated with urogenital ageing: a simple diagnostic test and the effect of the route of hormone administration.
M. Notelovitz (1995)
Climacteric symptoms among women aged 60-62 in Linköping, Sweden, in 1986.
G. Berg (1988)
The vaginal epithelium in the postmenopause--cytology, histology and pH as methods of assessment.
K. Nilsson (1995)
Local Treatment of Urogenital Atrophy with an Estradiol-Releasing Vaginal Ring: A Comparative and a Placebo-Controlled Multicenter Study
F. Casper (1999)
Factors influencing vaginal cytology, pH and bacterial flora in elderly women
I. Milsom (1993)
Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy.
P. Smith (1993)
Sexuality and Menopause
P. Sarrel (1990)
Vaginal pH and parabasal cells in postmenopausal women.
S. Brizzolara (1999)
Prevalence of Genitourinary Symptoms in the Late Menopause
C. Iosif (1984)
Diagnosis and treatment of atrophic vaginitis.
G. Bachmann (2000)
Postmenopausal Urinary Incontinence: Comparison Between Non‐Estrogen-Supplemented and Estrogen‐Supplemented Women
J. A. Fantl (1988)
Estrogen deprivation and vaginal function in postmenopausal women.
J. P. Semmens (1982)
A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy.
L. Henriksson (1994)
Vaginal Administration of Low-Dose Conjugated Estrogens: Systemic Absorption and Effects on the Endometrium
V. Handa (1994)
The maturation value.
A. Meisels (1967)

This paper is referenced by
Klinische Relevanz des urogenitalen Syndroms der Menopause
Ludwig Kiesel (2017)
Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
F. Labrie (2015)
Vaginal pH-Balanced Gel for the Control of Atrophic Vaginitis Among Breast Cancer Survivors: A Randomized Controlled Trial
Yoo-Kyung Lee (2011)
Vaginal microbiota and genitourinary menopausal symptoms: a cross-sectional analysis
Caroline M. Mitchell (2017)
Vaginal symptoms in postmenopausal women: self-reported severity, natural history, and risk factors
A. Huang (2010)
A Randomized Clinical Trial of the Impact of Local Estrogen on Postoperative Tissue Quality After Vaginal Reconstructive Surgery
D. Karp (2012)
Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy
S. Palacios (2016)
Urinary incontinence: newer pharmacotherapeutic trends
M. Huggins (2003)
Genital Prolapse, Urogenital Atrophy, and Sexual Dysfunction
M. Neimark (2008)
Patterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women's Health Initiative
M. Gass (2011)
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone)
D. Archer (2015)
Hormone replacement and breast cancer.
M. Castiglione-Gertsch (2004)
Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction.
Susan R Davis (2013)
Vaginal rugae: measurement and significance
J. Whiteside (2005)
The Effect of Vaginal Microablative Fractional CO2 Laser Treatment on Vaginal Cytology
P. Takacs (2020)
Hormonal Influences on Continence
D. Robinson (2009)
Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women
K. B. Levine (2008)
Comparison of Pueraria mirifica gel and conjugated equine estrogen cream effects on vaginal health in postmenopausal women
Narathorn Suwanvesh (2017)
Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy
C. Bouchard (2015)
Rethinking the Approach to Managing Postmenopausal Vulvovaginal Symptoms.
Alison J. Huang (2018)
Obesity and gynaecologic issues in teenagers Related review: Body morphology and its impact on adolescent and pediatric gynecology, with a special emphasis on polycystic ovary syndrome
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause
F. Labrie (2016)
Comparison of the effects of Pueraria mirifica gel and of placebo gel on the vaginal microenvironment of postmenopausal women with Genitourinary Syndrome of Menopause (GSM).
Chuleekorn Sritonchai (2020)
J 2 – Urogenitales Altern der Frau
E. Petri (2007)
Le syndrome génito-urinaire de la ménopause
Teddy Linet (2017)
Chapter 12 – Evidence for pelvic floor physical therapy in the elderly
M. Sherburn (2007)
Day-to-Day Impact of Vaginal Aging questionnaire: a multidimensional measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women
A. Huang (2015)
Vaginal atrophy and sexual dysfunction in current users of systemic postmenopausal hormone therapy.
S. Indhavivadhana (2010)
Prevalencia de la sintomatología urogenital en mujeres indígenas colombianas en posmenopausia
Alvaro Monterrosa-Castro (2012)
Good Clinical Practice in Diagnosis of Vulvovaginal Symptoms-Reply.
Caroline M. Mitchell (2018)
Genitourinary Changes with Aging.
Caroline M. Mitchell (2018)
Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief
N. Panay (2007)
See more
Semantic Scholar Logo Some data provided by SemanticScholar